Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Undergraduate Student Research Awards (USRA)

University of Alberta

$6,000.00

Improving Care for Individuals with Disorders of Lateralized Overgrowth

FY 2025-26

Summary
Disorders of lateralized overgrowth (LO) affect approximately 1 in 3000 individuals. In LO, a segment of the body is overgrown/disproportionately large. Some of these conditions are isolated (no other health risks), while others are associated with vascular anomalies, lymphatic malformations, vascular birthmarks and increased risks of developing pediatric cancers. The cause of LO is activating mutations in genes that promote cellular growth in a proportion of the body's cells. In some individuals the causative mutation can be identified, while in others it is unknown. Many of these genes have been well studied in the field of oncology and have medications designed to target them. Many previously untreatable disorders of LO may now benefit from a personalized medicine approach by repurposing these medications. The challenge in the clinic is to determine which patients may benefit from genetic investigations leading to changes in their management. There are currently no published clinical care pathways for these patients. We propose to undertake a scoping review of the contemporary medical literature with the goal of improving patient care pathways for individuals with LO. We will follow the PRISMA-ScR approach (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews). The objectives of the scoping review are to determine the yield of genetic testing, the available types of testing, who benefits from testing, which genes are potentially treatable with medications and what types of clinical trials are published. The outcome of this research is expected to lead to improved patient care pathways, decreased healthcare expenditures and show gaps in the medical literature for future research studies.
Program
Undergraduate Student Research Awards (USRA)
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
531026
Name
Ibrahim Aishat
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Improving Care for Individuals with Disorders of Lateralized Overgrowth
Programtype2
Miscellaneous Programs
Orgnameinp2
University of Alberta
Cihramount2
$6,000
Cihrequipment2
$0
Programname2
Undergraduate Student Research Awards (USRA)
Keyworddelim
Clinical Care Pathways; Genes; Lateralized Overgrowth; Lymphatic Malformations; Mutations; Patients; Pediatric Cancers; Testing; Vascular Anomalies; Vascular Birthmarks
Abstract
Disorders of lateralized overgrowth (LO) affect approximately 1 in 3000 individuals. In LO, a segment of the body is overgrown/disproportionately large. Some of these conditions are isolated (no other health risks), while others are associated with vascular anomalies, lymphatic malformations, vascular birthmarks and increased risks of developing pediatric cancers. The cause of LO is activating mutations in genes that promote cellular growth in a proportion of the body's cells. In some individuals the causative mutation can be identified, while in others it is unknown. Many of these genes have been well studied in the field of oncology and have medications designed to target them. Many previously untreatable disorders of LO may now benefit from a personalized medicine approach by repurposing these medications. The challenge in the clinic is to determine which patients may benefit from genetic investigations leading to changes in their management. There are currently no published clinical care pathways for these patients. We propose to undertake a scoping review of the contemporary medical literature with the goal of improving patient care pathways for individuals with LO. We will follow the PRISMA-ScR approach (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews). The objectives of the scoping review are to determine the yield of genetic testing, the available types of testing, who benefits from testing, which genes are potentially treatable with medications and what types of clinical trials are published. The outcome of this research is expected to lead to improved patient care pathways, decreased healthcare expenditures and show gaps in the medical literature for future research studies.
Competitiondate
202505
Approvedterm2
0 yr 4 mths
Pinamesdelim
Ibrahim, Aishat
Approvedterm
0 an 4 mois
Cihrcontribution2
~ $6,000~ $0~
University of Alberta - $6,000 Grant (2025-26) | Canada Spends